Feedback requested: Pfizer Comirnaty XBB.1.5 Pediatric Naming Conventions

Hi everyone,

We'd like to thank those stakeholders who provided their feedback. Based on our conversations and needs of those who use the public picklist fields in the CVC, the CVC team has made a decision to distinguish the two Pfizer Comirnaty XBB.1.5 pediatric vaccines by whether or not it should be diluted. The CVC Public Picklist and Clinician Picklist Terms will be as follows:

1. Diluent Not Required
ConceptID: 51501000087108
FSN: COMIRNATY Omicron XBB.1.5 messenger ribonucleic acid 10 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)
CVC Public Picklist Term: Pfizer-BioNTech Comirnaty Omicron XBB.1.5 DO NOT DILUTE COVID-19 mRNA pediatric
CVC Clinician Picklist Term: Pfizer-BioNTech Comirnaty Omicron XBB.1.5 DO NOT DILUTE pediatric (COVID-19)

2. Diluent Required
ConceptID: 51621000087101
FSN: COMIRNATY Omicron XBB.1.5 messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)
CVC Public Picklist Term: Pfizer-BioNTech Comirnaty Omicron XBB.1.5 DILUTE PRIOR TO USE COVID-19 mRNA pediatric
CVC Clinician Picklist Term: Pfizer-BioNTech Comirnaty Omicron XBB.1.5 DILUTE PRIOR TO USE pediatric (COVID-19)

Please don't hesitate to let us know if you have any questions.

Thank you,
Taylor

For BC our current UI tradename proposed dropdowns are following:
Maroon Cap--> "COMIRNATY 6m-4y Omicron XBB.1.5 3mcg (Pfizer)"

Blue Cap---> "COMIRNATY 5-11y Omicron XBB.1.5 10mcg (Pfizer)"

Gray Cap---> "COMIRNATY Omicron XBB.1.5 30mcg (Pfizer)"

BC has a citizen submission portal and thus we will have to configure to differentiate the product for the "orange cap" and look forward to suggestions from other jurisdictions. Thanks!

For BC our current UI tradename proposed dropdowns are following:
Maroon Cap--> "COMIRNATY 6m-4y Omicron XBB.1.5 3mcg (Pfizer)"

Blue Cap---> "COMIRNATY 5-11y Omicron XBB.1.5 10mcg (Pfizer)"

Gray Cap---> "COMIRNATY Omicron XBB.1.5 30mcg (Pfizer)"

BC has a citizen submission portal and thus we will have to configure to differentiate the product for the "orange cap" and look forward to suggestions from other jurisdictions. Thanks!

Hi everyone,

As discussed at the PHSC call on Thursday, October 5th, we are seeking feedback from the community on naming conventions and how to best differentiate between the Pfizer-BioNTech Comirnaty XBB.1.5 pediatric vaccines. Specifically, these concepts are:

51621000087101 |COMIRNATY Omicron XBB.1.5 messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)|
Current Preferred Term (PT): COVID-19 COMIRNATY Omicron XBB.1.5 pediatric 10 mcg/0.2 mL mRNA PB

and

51501000087108 ||COMIRNATY Omicron XBB.1.5 messenger ribonucleic acid 10 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)|
Current Preferred Term (PT): COVID-19 COMIRNATY Omicron XBB.1.5 pediatric 10 mcg/0.3 mL mRNA PB

Ontario's suggestion was to differentiate based on whether the product required a diluent or not (i.e. "DO NOT DILUTE" and "DILUENT REQUIRED").

If stakeholders have feedback, we kindly ask that you post in this forum to share your suggestions. Given that this is time sensitive, we are asking that stakeholders submit their feedback by end of day, Thursday, October 12th.

Thank you,
Taylor